LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 15 of 15: Calculated dose-response metrics. - Dataset (ID:20252)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | GR_AOC |
|---|---|---|
| MCF 10A | Enzastaurin | -0.0030 |
| Hs 578T | Enzastaurin | -0.0025 |
| BT-20 | TGX221 | -0.0004 |
| SK-BR-3 | SB590885 | 0.0014 |
| SK-BR-3 | R406 | 0.0017 |
| MCF7 | Vemurafenib | 0.0026 |
| MDA-MB-231 | Imatinib | 0.0035 |
| MCF 10A | Linifanib | 0.0081 |
| MCF 10A | Sirolimus | 0.0092 |
| MCF7 | PHA-665752 | 0.0102 |
| MCF7 | Erlotinib | 0.0109 |
| BT-20 | SB590885 | 0.0118 |
| MDA-MB-231 | Linifanib | 0.0133 |
| SK-BR-3 | Vemurafenib | 0.0135 |
| SK-BR-3 | PD184352 | 0.0135 |
| MCF 10A | PLX-4720 | 0.0137 |
| MCF 10A | CP724714 | 0.0142 |
| Hs 578T | CP466722 | 0.0186 |
| MCF7 | Ruxolitinib | 0.0218 |
| MCF 10A | Nintedanib | 0.0234 |
| MCF7 | CP466722 | 0.0241 |
| Hs 578T | Gefitinib | 0.0259 |
| MCF 10A | CP466722 | 0.0269 |
| BT-20 | CP466722 | 0.0302 |
| Hs 578T | XL147 | 0.0325 |